Last updated: August 29, 2026
DOPTELET SPRINKLE is a formulation-extension strategy for avatrombopag, marketed by Swedish specialty-pharmaceutical company Sobi. Its commercial value depends less on creating a new mechanism than on expanding DOPTELET access to patients who have difficulty swallowing tablets, particularly pediatric patients and patients with chronic liver disease. Sobi does not publicly report revenue for DOPTELET SPRINKLE as a standalone product, so its financial trajectory must be assessed through the broader DOPTELET franchise.
What is DOPTELET SPRINKLE and who manufactures it?
DOPTELET SPRINKLE is an oral granule formulation of avatrombopag maleate. DOPTELET is an orally administered thrombopoietin receptor agonist that increases platelet production.
Sobi acquired Dova Pharmaceuticals, DOPTELET's original commercial owner, in 2019. Sobi controls the principal global commercial rights and markets DOPTELET in the United States and other territories.
| Attribute |
DOPTELET SPRINKLE |
| Active ingredient |
Avatrombopag maleate |
| Drug class |
Oral thrombopoietin receptor agonist |
| Manufacturer/commercial owner |
Swedish Orphan Biovitrum AB, or Sobi |
| Primary therapeutic area |
Thrombocytopenia |
| Existing DOPTELET dosage form |
Oral tablets |
| Sprinkle dosage form |
Oral granules administered with soft food |
| Principal commercial rationale |
Improved administration for patients unable to swallow tablets |
| Primary competitor classes |
Lusutrombopag, eltrombopag, romiplostim, platelet transfusion |
DOPTELET's established U.S. indications include treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure and adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.[1]
The Sprinkle formulation is strategically important because thrombocytopenia is common in pediatric liver disease, while pediatric patients often have limited access to convenient oral platelet-raising therapies. A formulation that can be mixed with soft food also addresses administration constraints in patients with dysphagia, feeding difficulties, or enteral medication requirements.
What market does DOPTELET SPRINKLE address?
DOPTELET SPRINKLE operates in a specialized market with two distinct demand pools.
Chronic liver disease and procedure preparation
Patients with chronic liver disease can develop thrombocytopenia from portal hypertension, splenic sequestration, impaired thrombopoietin production, and advanced liver dysfunction. Before an invasive procedure, physicians may use an oral thrombopoietin receptor agonist to raise platelet counts and reduce or avoid platelet transfusion.
The procedure-preparation market has several commercial advantages:
- Treatment courses are short and tied to scheduled procedures.
- Physicians can measure the need for therapy against a specific platelet threshold.
- Avoiding transfusion can reduce hospital logistics and blood-product utilization.
- Oral treatment can shift care away from transfusion centers and inpatient workflows.
DOPTELET competes directly with Mulpleta, the U.S. brand for lusutrombopag. Both products are used before procedures in adults with chronic liver disease, but their dosing schedules, clinical data, reimbursement treatment, and institutional adoption differ.
Chronic immune thrombocytopenia
Chronic immune thrombocytopenia is a recurring-treatment market. Patients may remain on therapy for extended periods, creating more durable revenue than short peri-procedural courses.
The main branded competitors include:
- Promacta, or eltrombopag, marketed by Novartis;
- Nplate, or romiplostim, marketed by Amgen;
- Doptelet, or avatrombopag, marketed by Sobi.
DOPTELET has an advantage over eltrombopag in that it does not require the same level of dietary separation from polyvalent cations. It also avoids the injection burden associated with romiplostim. Its disadvantages include a smaller commercial footprint and the need to establish platelet response through titration and monitoring.
How does DOPTELET SPRINKLE compare with competing drugs?
| Product |
Active ingredient |
Administration |
Main relevant markets |
Commercial strength |
| DOPTELET/DOPTELET SPRINKLE |
Avatrombopag |
Oral tablet or granules |
Chronic liver disease, chronic ITP |
Oral convenience and formulation expansion |
| Mulpleta |
Lusutrombopag |
Oral tablet |
Chronic liver disease before procedures |
Direct procedural competitor |
| Promacta |
Eltrombopag |
Oral tablet or suspension in some markets |
ITP and other thrombocytopenic disorders |
Large installed base and broad clinical use |
| Nplate |
Romiplostim |
Subcutaneous injection |
Chronic ITP |
Established physician familiarity |
| Platelet transfusion |
Donor platelets |
Intravenous transfusion |
Acute procedural support |
Immediate platelet increase, but logistical and safety burdens |
The Sprinkle formulation's strongest competitive position is administration, not pharmacology. It may improve adherence and reduce tablet-swallowing barriers, but it does not automatically displace low-cost platelet transfusion or established chronic ITP therapies.
What is the financial trajectory of the DOPTELET franchise?
Sobi reports DOPTELET revenue at the brand or franchise level rather than separately identifying DOPTELET SPRINKLE. The product has been one of Sobi's key growth assets since the Dova acquisition.
Public company reporting shows a multi-year growth trajectory driven by:
- Continued U.S. uptake in chronic liver disease.
- Expansion in chronic immune thrombocytopenia.
- Increased physician familiarity with oral thrombopoietin receptor agonists.
- International commercialization.
- Lifecycle management through additional dosage forms and patient populations.
DOPTELET revenue reached the multi-billion-Swedish-kronor range in Sobi's annual reporting during the early 2020s. The company has not disclosed a separate revenue line for DOPTELET SPRINKLE, preventing a product-specific assessment of launch sales, gross margin, or contribution to consolidated growth.[2][3]
| Financial issue |
Assessment |
| Standalone Sprinkle revenue |
Not separately disclosed |
| Revenue visibility |
High at the DOPTELET franchise level; low for the Sprinkle formulation alone |
| Growth driver |
Volume expansion and indication penetration |
| Margin profile |
Expected to be attractive relative to transfusion-related care, but formulation-specific margin is undisclosed |
| Key commercial risk |
Cannibalization of tablet sales rather than entirely new patient demand |
| Key upside |
Pediatric access and improved use in patients unable to swallow tablets |
| Reporting company |
Sobi |
| Primary geographic market |
United States, with international expansion |
The formulation could produce three different financial outcomes:
- Incremental growth if it reaches patients who would otherwise receive transfusions or no oral therapy.
- Revenue protection if it prevents switching to competing formulations.
- Limited net growth if physicians simply substitute Sprinkle for tablets in existing DOPTELET users.
The third scenario is likely in established adult markets. The first two scenarios are more relevant to pediatric and administration-constrained populations.
When does DOPTELET lose exclusivity?
DOPTELET's loss-of-exclusivity analysis depends on the specific indication, formulation, patent, regulatory exclusivity, and jurisdiction. The original tablet product has an earlier commercial entry date than any later Sprinkle formulation. A new formulation may receive separate patent protection, but it does not reset all exclusivity attached to the active ingredient.
In the United States, relevant protection may include:
- Patents listed in the FDA Orange Book;
- Formulation patents covering granules, excipients, particle size, or administration;
- Method-of-use patents covering treatment of thrombocytopenia;
- Pediatric exclusivity, if granted;
- Regulatory exclusivity associated with a new dosage form or indication.
A generic tablet challenger may not be able to market a Sprinkle product without developing and filing a separate formulation application. Conversely, a Sprinkle-specific patent would not necessarily block all tablet-based generic entry.
Paragraph IV challenge risk
A generic applicant could submit an abbreviated new drug application with a Paragraph IV certification alleging that listed DOPTELET patents are invalid, unenforceable, or not infringed. The risk profile differs by product:
| Challenge target |
Likely legal issue |
| Avatrombopag tablet |
Active-ingredient, formulation, or method-of-use patents |
| Sprinkle granules |
Granule composition, release characteristics, packet design, or administration method |
| Chronic liver disease use |
Method-of-use patent scope and labeling carve-outs |
| Chronic ITP use |
Indication-specific patent claims |
| Pediatric use |
Pediatric indication and formulation claims |
A generic tablet entrant could pressure adult pricing before a Sprinkle competitor becomes commercially viable. The Sprinkle product may therefore have a longer practical life in pediatric use than in the mature adult tablet market, depending on patent coverage and FDA approval timing.
What is the FDA regulatory status of DOPTELET SPRINKLE?
The FDA regulatory value of DOPTELET SPRINKLE depends on whether the product is approved as a new dosage form, an expanded indication, or both. The core regulatory advantages are:
- Use of an established active ingredient;
- Existing human safety and pharmacology data for avatrombopag;
- Potential reliance on bridging data rather than a wholly new clinical program;
- A focused patient population with a clear administration need.
The primary regulatory risks are formulation performance, dose uniformity, food administration, stability, and the ability to demonstrate that granules produce an acceptable exposure profile relative to tablets.
The product's regulatory differentiation is strongest where the tablet formulation is clinically impractical. FDA approval in pediatric chronic liver disease would create a more defensible commercial niche than a simple reformulation for adults who can already swallow tablets.
Which companies challenge DOPTELET in the market?
DOPTELET faces competition from both branded drugs and standard hospital practice.
Branded competitors
Promacta has the broadest historical presence in thrombocytopenia. Nplate has a durable position in chronic ITP but requires injection. Mulpleta is the most direct procedural competitor in chronic liver disease.
Non-drug alternatives
Platelet transfusion remains a major substitute, particularly when an immediate platelet increase is needed or when reimbursement and hospital protocols favor transfusion. Splenectomy, immunosuppressive treatment, corticosteroids, intravenous immunoglobulin, and other ITP therapies also compete for treatment budget and physician attention.
DOPTELET SPRINKLE's commercial case is strongest when it reduces a practical barrier to oral therapy. Its case is weaker when the clinical setting requires rapid platelet correction, where transfusion or injectable therapy may remain preferable.
What licensing and litigation issues affect DOPTELET?
Sobi's acquisition of Dova Pharmaceuticals transferred control of DOPTELET and associated commercial and intellectual-property assets to Sobi.[4] The transaction provided Sobi with a marketed hematology product and reduced its reliance on internal pipeline assets for near-term revenue growth.
The central legal issues are likely to be:
- Orange Book patent listings for avatrombopag products;
- Patent term and pediatric extensions;
- Paragraph IV filings against tablet or granule products;
- Settlement agreements with generic applicants;
- Patent ownership or licensing obligations inherited through the Dova acquisition;
- Potential disputes over formulation and method-of-use claims.
A definitive assessment of current litigation and settlement exposure requires live review of FDA Orange Book entries, ANDA litigation dockets, and Sobi's current regulatory filings. Product-level revenue and formulation-specific legal outcomes are not disclosed in Sobi's historical financial statements.
How strong is the DOPTELET patent estate?
The estate is commercially meaningful but likely layered rather than dependent on a single broad monopoly. The strongest protection would come from claims covering:
- Avatrombopag composition of matter;
- Specific granule or sprinkle formulations;
- Stable oral dosage forms;
- Dosing regimens for chronic liver disease;
- Pre-procedure platelet elevation;
- Chronic immune thrombocytopenia treatment;
- Pediatric administration.
Formulation patents can delay direct Sprinkle competition, but they may not prevent generic entry using a different oral dosage form. Method-of-use patents can provide additional protection if the approved label and physician practice align with the claims. Their value is lower where a generic applicant can omit the patented indication through a skinny label.
What generic launch scenarios exist?
The most likely launch sequence is:
- Tablet generic entry creates the first major pricing pressure.
- Adult chronic ITP pricing declines before pediatric demand matures.
- Sprinkle-specific competition follows only if market size supports formulation development.
- Sobi protects share through pediatric labeling, supply reliability, and patient-support programs.
- Net franchise revenue depends on whether Sprinkle expands treatment or shifts existing users from tablets.
The key commercial variable is substitution. A successful Sprinkle launch can protect the DOPTELET franchise even if it adds little standalone revenue.
Key Takeaways
- DOPTELET SPRINKLE is an avatrombopag lifecycle-management product owned and commercialized by Sobi.
- Its main differentiation is administration convenience, particularly for pediatric patients and patients unable to swallow tablets.
- The broader DOPTELET franchise has been a material Sobi growth asset since the Dova acquisition.
- Sobi does not separately disclose DOPTELET SPRINKLE revenue, margins, or patient numbers.
- The product competes with Mulpleta, Promacta, Nplate, platelet transfusion, and other thrombocytopenia treatments.
- The principal commercial risk is tablet-to-Sprinkle substitution without meaningful patient expansion.
- The principal upside is incremental use in pediatric chronic liver disease and administration-constrained patients.
- Generic risk will depend on Orange Book patents, formulation claims, method-of-use patents, Paragraph IV litigation, and settlement terms.
- Tablet generic entry could precede and partially decouple from Sprinkle-specific competition.
FAQs
Is DOPTELET SPRINKLE a new active ingredient?
No. It uses avatrombopag maleate, the same active ingredient used in DOPTELET tablets.
Does DOPTELET SPRINKLE replace platelet transfusion?
It can reduce the need for transfusion in selected planned-procedure settings, but it is not a universal replacement for transfusion, especially when an immediate platelet increase is required.
Is DOPTELET SPRINKLE approved for chronic immune thrombocytopenia?
The established DOPTELET tablet label includes adult chronic immune thrombocytopenia. The commercial scope of the Sprinkle formulation depends on its approved label and dosage-form-specific regulatory status.
Will a tablet generic automatically be able to sell a Sprinkle product?
No. A tablet generic approval does not automatically authorize a granule product. A manufacturer would generally need an approved formulation that satisfies FDA requirements and avoids applicable Sprinkle-specific patents.
Why does DOPTELET SPRINKLE matter financially if Sobi does not report separate sales?
Its financial value may arise through franchise protection, new patient access, pediatric expansion, and reduced switching to competing therapies. Those effects are captured in total DOPTELET revenue rather than a separate Sprinkle line.
References
-
U.S. Food and Drug Administration. (2024). DOPTELET (avatrombopag maleate) tablets: Prescribing information. FDA.
-
Swedish Orphan Biovitrum AB. (2023). Annual report 2023. Sobi.
-
Swedish Orphan Biovitrum AB. (2024). Interim and annual financial reporting for DOPTELET and the hematology portfolio. Sobi.
-
Swedish Orphan Biovitrum AB. (2019). Sobi completes acquisition of Dova Pharmaceuticals. Sobi.
